Common questions about Infanrix (FAQ)
Q: What is the difference between Infanrix and Infanrix-IPV?
Infanrix is the vaccine for Diphtheria, Tetanus, and acellular Pertussis (DTaP). Official product information shows that Infanrix-IPV is a different combination product that also includes protection against Inactivated Poliovirus (IPV).
This means Infanrix-IPV protects against four diseases, while Infanrix protects against three.
Q: Are the components of Infanrix found in other similar DTaP vaccines?
Yes, the basic components—diphtheria toxoid, tetanus toxoid, and acellular pertussis antigens—are common across similar DTaP products.
Official documents indicate that the specific number and concentration of the pertussis antigens may vary between different manufacturers’ brands.
Q: What does the 'acellular' pertussis component in Infanrix mean?
The term 'acellular' is used because this vaccine does not contain the entire whole pertussis bacterial cell.
Instead, it includes only purified, inactive components (antigens) from the Bordetella pertussis bacteria. This design is used to stimulate the immune system.
Q: How long do the typical side effects from Infanrix usually last?
According to regulatory safety documents, common side effects such as local pain, fever, or irritability are generally transient and resolve quickly.
Reactions at the injection site, like redness or a temporary mass, are typically observed to persist for up to a few days.
Q: What is the reported frequency of a severe allergic reaction (anaphylaxis) to Infanrix?
Official regulatory documents classify anaphylactic reactions (severe allergic reactions) as Rare.
This means that a severe allergic reaction is observed in less than 1 in 1,000 recipients but in 1 in 10,000 recipients or more.
Q: What is a 'Hypotonic-Hyporesponsive Episode' (HHE) and how often is it reported with Infanrix?
A Hypotonic-Hyporesponsive Episode (HHE) is a serious, but rare, event documented in official product information.
It is classified as a collapse or shock-like state that is observed to occur within 48 hours following vaccination.
Q: Why does the package insert mention substances like formaldehyde or neomycin?
Regulatory documents mention these substances because they may be present in trace amounts, having been used during the manufacturing process of the vaccine components.
Hypersensitivity (severe allergic reaction) to any of these trace substances is listed in the official documents as a contraindication.
Q: Are there specific warnings for children with a personal or family history of fever-related fits (convulsions)?
Official product information notes that a family history of convulsions or Sudden Infant Death Syndrome (SIDS) is not a contraindication for the vaccine.
However, a personal history of fever-related fits (febrile convulsions) is documented as requiring special attention, which involves monitoring by the healthcare provider after administration.
Q: When can a child be considered fully protected after starting the Infanrix series?
Protection is generally assessed in studies one month after the completion of the primary series, which is typically the third dose.
Research evidence indicates that seroprotection rates against Diphtheria and Tetanus antigens often reach high levels (96%–100%) one month after this third dose.
Q: What is the purpose of the recommended booster doses of Infanrix?
Studies and official schedules indicate that booster doses are recommended to sustain the immune response over time.
The level of protective antibodies against the diseases, particularly the pertussis component, is observed to progressively decline several years after the primary course is completed.
Q: Can Infanrix be administered at the same time as other routine childhood vaccines?
Yes, regulatory documents state that Infanrix can be administered concurrently with other routine childhood vaccines.
However, strict logistical restrictions require that it must be given at a separate injection site and should not be physically mixed with any other vaccine in the same syringe.
Q: Do official safety sources connect Infanrix vaccination to Sudden Infant Death Syndrome (SIDS)?
Official product information clarifies that a family history of Sudden Infant Death Syndrome (SIDS) is not listed as a contraindication for the use of the vaccine.
Q: Why is the Infanrix primary vaccine schedule structured with specific intervals between doses?
The specific dosing intervals (e.g., 4 to 8 weeks) are derived from clinical studies.
These intervals are designed to ensure that the patient’s immune system generates and sustains a sufficient, long-lasting protective immune response throughout the entire primary series.
Q: What is the difference in pertussis components between Infanrix and older whole-cell pertussis vaccines?
Infanrix is an acellular vaccine, which means it uses only purified components (toxoids and antigens) of the pertussis bacterium. Older whole-cell vaccines contained the entire inactivated bacterial cell.
Official documents note that acellular vaccines are generally associated with lower reported rates of mild to moderate adverse reactions, such as fever.
Q: What is the significance of the manufacturer's post-marketing surveillance data for Infanrix?
Post-marketing surveillance involves the ongoing collection of data after a product has been approved and is used by the public.
This process evaluates the vaccine’s safety and tolerability in routine clinical practice, which is used to evaluate the product’s safety and tolerability in routine clinical practice.
Q: Are there any known issues regarding the interchangeability of Infanrix with other manufacturers' DTaP-containing vaccines?
While it is preferred to complete the primary series using the same brand, official guidance states that DTaP products are generally interchangeable for series completion.
If the original product brand is unavailable or unknown, another brand may be used to continue the immunization schedule.
Q: Does Infanrix (or Infanrix hexa) provide protection against all types of Haemophilus influenzae?
The component included in some combination formulations that protects against Haemophilus influenzae type b (Hib) only targets diseases caused by that specific type b capsular serotype.
It does not provide protection against other serotypes of H. influenzae or against meningitis caused by other types of organisms.
Q: Is there a way for a parent to verify the full list of components or inactive ingredients in the Infanrix vaccine?
The complete list of excipients (inactive ingredients) is legally documented in official regulatory resources.
This list is available in the corresponding section of the Summary of Product Characteristics (SmPC) or the FDA Package Insert.
Q: Are there different versions of Infanrix used in different national immunization programs?
Yes, the vaccine is supplied in different versions globally, such as Infanrix, Infanrix-IPV, and Infanrix Hexa.
These products contain different combinations of antigens to align with the specific immunization schedule and requirements of various national health programs.
Q: How effective is Infanrix in providing protection against diphtheria and tetanus?
Clinical trials for this vaccine show high levels of immunogenicity (immune response).
Seroprotection rates against Diphtheria and Tetanus antigens are typically reported to range between 96% and 100% after the completion of the primary three-dose series.
Q: How do clinical studies define a 'severe' adverse event reported for Infanrix?
Clinical studies define severe reactions requiring special consideration based on specific clinical criteria and timeframes.
These can include a high temperature of 40.0 C (104 F) or more within 48 hours, or a period of persistent, inconsolable crying lasting three hours or longer, occurring within 48 hours of vaccination.
Q: What does it mean if a child experiences a temporary low platelet count (thrombocytopenia) after receiving Infanrix?
Thrombocytopenia (a low platelet count) is a condition for which caution is required when administering the vaccine due to the risk of bleeding or bruising from the intramuscular injection.
Post-vaccination thrombocytopenia is also listed as a Rare adverse event.
Q: What signs or symptoms should a parent monitor for in the days immediately following the Infanrix injection?
The monitoring focus following administration commonly includes expected reactions such as fever, irritability, and soreness at the injection site.
Regulatory warnings also list more serious but rare events that require medical review, such as a high temperature of 40.0 C or more, a collapse or shock-like state (HHE), or convulsions.
Q: What does the long-term follow-up data show regarding the safety of Infanrix?
Long-term follow-up data, including post-licensure surveillance, is collected to evaluate the product’s long-term safety profile when used in routine immunization.
Official safety notes state that respiratory monitoring for 48 to 72 hours may be considered for very premature infants after the primary series due to the potential for apnoea (breathing cessation).
Q: Is Infanrix appropriate for infants who were born very prematurely?
Official safety information notes that the potential for apnoea (breathing cessation) is a factor for consideration when administering the primary series to very premature infants (those born at le 28 weeks of gestation).
The product label notes that respiratory monitoring for 48 to 72 hours may be appropriate for these infants after the injection.
Q: Can a child with a minor illness, like a cold, still receive Infanrix?
Official regulatory guidelines state that the presence of a minor infection is generally not a reason to postpone the vaccination.
Postponement of administration is indicated if the child is suffering from an acute severe illness accompanied by a high fever.
Q: Can the simultaneous administration of Infanrix and a pneumococcal vaccine affect the immune response to either?
Official documents note that the simultaneous administration of Infanrix with the Pneumococcal Conjugate Vaccine is associated with an increased incidence of fever reactions.
When given at different injection sites, there is no clear regulatory statement of a significant negative effect on the immune response to either vaccine.
